Payment overview · 2025
General Payments
$916.56
46 reported records · 13 companies
Healthcare provider profile · identity verified
Farooque Ahmed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EL PASO, TX · NPI 1164424982
Verified facts
What the public records show
CMS Open Payments records show Farooque Ahmed, MD received $916.56 in general payments during 2025 across 46 reported records.
Abbott Laboratories accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Entresto, Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 375 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $272.65 | 29.8% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $216.56 | 23.6% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $109.79 | 12.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.37 | 10.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.40 | 4.6% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $33.75 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.57 | 3.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.93 | 2.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $22.02 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.83 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.71 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.74 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.24 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $916.56 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $272.65 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.24 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $109.79 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.37 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.85 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $32.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.50 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.50 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.50 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 375 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 37 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 112 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
112 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
37 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
375 | 85 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 614 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 487 | 111 |
| Metformin Hcl | Metformin Hcl | 422 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 413 | 113 |
| Memantine Hcl | Memantine Hcl | 410 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 396 | 90 |
| Eliquis | Apixaban | 375 | 85 |
| Furosemide | Furosemide | 361 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 329 | 101 |
| Gabapentin | Gabapentin | 318 | 91 |
| Lisinopril | Lisinopril | 279 | 90 |
| Donepezil Hcl | Donepezil Hcl | 268 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 256 | 44 |
| Losartan Potassium | Losartan Potassium | 256 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 53 |
| Mirtazapine | Mirtazapine | 227 | 47 |
| Sertraline Hcl | Sertraline Hcl | 221 | 42 |
| Carvedilol | Carvedilol | 219 | 50 |
| Trazodone Hcl | Trazodone Hcl | 208 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 81 |
| Buspirone Hcl | Buspirone Hcl | 166 | 33 |
| Simvastatin | Simvastatin | 163 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 157 | 32 |
| Finasteride | Finasteride | 156 | 45 |
| Famotidine | Famotidine | 142 | 35 |
| Risperidone | Risperidone | 142 | 19 |
| Alprazolam | Alprazolam | 139 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 53 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 132 | 49 |
| Spironolactone | Spironolactone | 130 | 47 |
| Celecoxib | Celecoxib | 124 | 49 |
| Tramadol Hcl | Tramadol Hcl | 122 | 43 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 117 | 44 |
| Montelukast Sodium | Montelukast Sodium | 117 | 37 |
| Fenofibrate | Fenofibrate Nanocrystallized | 116 | 28 |
| Farxiga | Dapagliflozin Propanediol | 112 | 27 |
| Nifedipine Er | Nifedipine | 111 | 18 |
| Januvia | Sitagliptin Phosphate | 110 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 60 |
| Ozempic | Semaglutide | 100 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 15 |
| Glimepiride | Glimepiride | 97 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 26 |
| Levetiracetam | Levetiracetam | 86 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 84 | suppressed |
| Omeprazole | Omeprazole | 84 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 38 |
| Jardiance | Empagliflozin | 78 | 27 |
| Lactulose | Lactulose | 78 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 21 |
| Prednisone | Prednisone | 73 | 43 |
| Megestrol Acetate | Megestrol Acetate | 71 | 29 |
| Potassium Chloride | Potassium Chloride | 68 | 24 |
| Venlafaxine Hcl | Venlafaxine Hcl | 65 | 12 |
| Xarelto | Rivaroxaban | 64 | 15 |
| Alendronate Sodium | Alendronate Sodium | 62 | 20 |
| Glipizide | Glipizide | 62 | 15 |
| Pregabalin | Pregabalin | 61 | 20 |
| Clonidine Hcl | Clonidine Hcl | 57 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 55 | 17 |
| Labetalol Hcl | Labetalol Hcl | 55 | 23 |
| Valsartan | Valsartan | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 14 |
| Gemtesa | Vibegron | 54 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 21 |
| Ibuprofen | Ibuprofen | 53 | 34 |
| Sucralfate | Sucralfate | 53 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 19 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 51 | suppressed |
| Calcium Acetate | Calcium Acetate | 50 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 50 | 24 |
| Sevelamer Carbonate | Sevelamer Carbonate | 50 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 48 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 48 | 20 |
| Amantadine | Amantadine Hcl | 47 | suppressed |
| Mounjaro | Tirzepatide | 47 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 29 |
| Tradjenta | Linagliptin | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Azithromycin | Azithromycin | 44 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 39 |
| Cefuroxime | Cefuroxime Axetil | 41 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Olanzapine | Olanzapine | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 14 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 11 |
| Entresto | Sacubitril/Valsartan | 37 | 21 |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | 12 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 35 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 15 |
| Allopurinol | Allopurinol | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 14 |
| Topiramate | Topiramate | 33 | suppressed |
| Meloxicam | Meloxicam | 32 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 13 |
| Metformin Hcl Er | Metformin Hcl | 30 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 18 |
| Colchicine | Colchicine | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Valproic Acid | Valproic Acid | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 15 |
| Repaglinide | Repaglinide | 24 | 11 |
| Cilostazol | Cilostazol | 23 | suppressed |
| Budesonide | Budesonide | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Caplyta | Lumateperone Tosylate | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Desvenlafaxine Er | Desvenlafaxine | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 13 | 13 |
| Nystatin | Nystatin | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $916.56 · 46 records | Abbott Laboratories | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, Tymlos, XYOSTED, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error